Molecularbiology of Basal Cell Carcinoma

Fabricius, Eva‐Maria; Hoffmeister, Bodo; Raguse, Jan-Dirk

doi:10.5772/27415

Cited by 1 publication

(2 citation statements)

References 201 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…cancer) [11]. Telomerase activity has been reported in cutaneous melanomas, using the TRAP assay, with increasing values from normal skin to benign nevi and to dysplastic nevi and finally to melanoma [29]. An association between increased telomerase activity and worse prognostic features, namely, ulceration, vascular invasion, mitotic rate and Breslow thickness has been described in melanoma [18,32,81,91,100].…”

Section: Telomerase Promoter Mutations In Skin Cancersmentioning

confidence: 99%

“…TERT promoter mutations are frequent in non-melanoma skin cancer, ranging from 39 to 74 % in sporadic basal cell carcinomas (BCC) [37,94,110] and present in up to 50 % of cases of squamous cell carcinoma (SCC) [3 7, 110].Telomerase activity has been detected in BCC using TRAP assay both in tumour and tumour-free margins, varying between 20 and 100 %, with less activity in the latter [29]. In the tumour-free margins, telomerase activity was found to be more prevalent in sun-exposed skin [105,119].…”

Section: Telomerase Promoter Mutations In Skin Cancersmentioning

confidence: 99%

See 1 more Smart Citation

Telomerase promoter mutations in cancer: an emerging molecular biomarker?

et al. 2014

View full text Add to dashboard Cite

Cell immortalization has been considered for a long time as a classic hallmark of cancer cells. Besides telomerase reactivation, such immortalization could be due to telomere maintenance through the "alternative mechanism of telomere lengthening" (ALT) but the mechanisms underlying both forms of reactivation remained elusive. Mutations in the coding region of telomerase gene are very rare in the cancer setting, despite being associated with some degenerative diseases. Recently, mutations in telomerase (TERT) gene promoter were found in sporadic and familial melanoma and subsequently in several cancer models, notably in gliomas, thyroid cancer and bladder cancer. The importance of these findings has been reinforced by the association of TERT mutations in some cancer types with tumour aggressiveness and patient survival. In the first part of this review, we summarize the data on the biology of telomeres and telomerase, available methodological approaches and nonneoplastic diseases associated with telomere dysfunction. In the second part, we review the information on telomerase expression and genetic alterations in the most relevant types of cancer (skin, thyroid, bladder and central nervous system) on record, and discuss the value of telomerase as a new biomarker with impact on the prognosis and survival of the patients and as a putative therapeutic target.

show abstract